Role of biologics in severe eosinophilic asthma – focus on reslizumab
Girolamo Pelaia,1 Alessandro Vatrella,2 Maria Teresa Busceti,1 Luca Gallelli,3 Mariaimmacolata Preianò,3 Nicola Lombardo,1 Rosa Terracciano,3 Rosario Maselli1 1Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia&r...
Main Authors: | Pelaia G, Vatrella A, Busceti MT, Gallelli L, Preianò M, Lombardo N, Terracciano R, Maselli R |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-07-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/role-of-biologics-in-severe-eosinophilic-asthma-ndash-focus-on-reslizu-peer-reviewed-article-TCRM |
Similar Items
-
Reslizumab in the management of poorly controlled asthma: the data so far
by: Maselli DJ, et al.
Published: (2016-08-01) -
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
by: Pelaia C, et al.
Published: (2017-10-01) -
Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
by: S. K. Zyryanov, et al.
Published: (2020-12-01) -
Successful treatment of refractory eosinophilic fasciitis with reslizumab
by: Mahta Mortezavi, MD, et al.
Published: (2020-09-01) -
Interleukin-5 in the Pathophysiology of Severe Asthma
by: Corrado Pelaia, et al.
Published: (2019-12-01)